Pliant Therapeutics, Inc. Financials
Pliant Therapeutics, Inc. (PLRX) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Pliant’s business model is still research-funded cash burn, with balance-sheet liquidity carrying the company more than earnings.
Reported net income was$149.3M , yet operating cash flow was-$128.3M . That disconnect means the profit figure is not describing the underlying engine of the business; with capex at only$374K and free cash flow at-$128.7M , the cash drain is overwhelmingly about funding operations and research rather than maintaining a capital-heavy asset base.
Cash was only
Spending remains development-led: R&D of
Financial Health Signals
Pliant Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Pliant Therapeutics, Inc. scores -5.67, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($73.7M) relative to total liabilities ($44.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Pliant Therapeutics, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Pliant Therapeutics, Inc. used $0.86 of operating cash (-$128.3M OCF vs $149.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Pliant Therapeutics, Inc. reported an operating loss of $156.4M against $2.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Pliant Therapeutics, Inc. generated $0 in revenue in fiscal year 2025.
Pliant Therapeutics, Inc.'s EBITDA was -$154.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 31.6% from the prior year.
Pliant Therapeutics, Inc. reported $149.3M in net income in fiscal year 2025. This represents a decrease of 29.0% from the prior year.
Pliant Therapeutics, Inc. earned -$2.43 per diluted share (EPS) in fiscal year 2025. This represents an increase of 30.0% from the prior year.
Cash & Balance Sheet
Pliant Therapeutics, Inc. recorded an outflow of $128.7M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 19.2% from the prior year.
Pliant Therapeutics, Inc. held $45.4M in cash against $0 in long-term debt as of fiscal year 2025.
Pliant Therapeutics, Inc. paid $0.00 per share in dividends in fiscal year 2025.
Margins & Returns
Pliant Therapeutics, Inc.'s ROE was 82.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 13.2 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Pliant Therapeutics, Inc. invested $109.2M in research and development in fiscal year 2025. This represents a decrease of 35.5% from the prior year.
Pliant Therapeutics, Inc. invested $374K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 90.3% from the prior year.
Not reported for fiscal year 2025.
PLRX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0-100.0% | $1.6M-83.7% | $9.7M+27.9% | $7.6M-81.9% | $41.8M-26.7% | $57.1M |
| R&D Expenses | N/A | $109.2M-35.5% | $169.3M+32.5% | $127.8M+31.8% | $96.9M+25.0% | $77.5M+17.2% | $66.2M+39.8% | $47.4M |
| SG&A Expenses | N/A | $47.2M-20.0% | $59.1M+1.9% | $57.9M+45.0% | $39.9M+45.0% | $27.6M+59.6% | $17.3M+58.0% | $10.9M |
| Operating Income | N/A | -$156.4M+31.5% | -$228.4M-24.0% | -$184.1M-44.8% | -$127.2M-30.4% | -$97.5M-134.2% | -$41.6M-3283.0% | -$1.2M |
| Interest Expense | N/A | $2.6M-15.4% | $3.0M+138.7% | $1.3M+60.2% | $791K | $0 | N/A | N/A |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | N/A | $149.3M-29.0% | $210.3M+30.4% | $161.3M+230.8% | -$123.3M-26.8% | -$97.3M-134.2% | -$41.5M-6482.1% | -$631K |
| EPS (Diluted) | — | -$2.43+30.0% | -$3.47-26.2% | -$2.75+6.5% | -$2.94-8.5% | -$2.71 | -$1.95 | -$4.22 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
PLRX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Total Assets | $225.2M-43.3% | $396.9M-22.5% | $512.2M+46.1% | $350.6M+58.5% | $221.2M-25.1% | $295.5M+148.2% | $119.1M |
| Current Assets | $196.4M-45.8% | $362.3M-28.3% | $505.5M+48.5% | $340.3M+62.5% | $209.4M-28.0% | $290.8M+159.8% | $111.9M |
| Cash & Equivalents | $45.4M-36.2% | $71.2M+12.6% | $63.2M+87.7% | $33.7M-34.8% | $51.7M+1.5% | $50.9M-40.7% | $85.8M |
| Accounts Receivable | N/A | N/A | $0-100.0% | $2.0M-0.8% | $2.0M-78.5% | $9.3M+31.6% | $7.1M |
| Total Liabilities | $44.0M-52.6% | $92.9M+140.7% | $38.6M+3.5% | $37.3M+68.2% | $22.2M+77.7% | $12.5M-93.6% | $195.4M |
| Current Liabilities | $16.4M-50.7% | $33.2M+16.5% | $28.5M+19.3% | $23.9M+42.1% | $16.8M+45.1% | $11.6M+41.9% | $8.2M |
| Long-Term Debt | $0-100.0% | $30.2M+200.5% | $10.1M+1.3% | $9.9M | $0 | N/A | N/A |
| Total Equity | $181.2M-40.4% | $304.1M-35.8% | $473.6M+51.1% | $313.3M+57.4% | $199.1M-29.7% | $283.1M+471.0% | -$76.3M |
| Retained Earnings | -$859.4M-21.0% | -$710.1M-42.1% | -$499.7M-47.7% | -$338.4M-57.3% | -$215.1M-82.5% | -$117.8M-54.4% | -$76.3M |
Not reported in any period shown, so not listed: Inventory, Goodwill.
PLRX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$70.9M | -$128.3M+17.5% | -$155.5M-33.6% | -$116.4M-23.0% | -$94.6M-25.4% | -$75.4M-102.4% | -$37.3M-1255.3% | -$2.8M |
| Capital Expenditures | $0 | $374K-90.3% | $3.8M+317.8% | $921K-47.7% | $1.8M-9.9% | $2.0M+27.5% | $1.5M+58.9% | $964K |
| Free Cash Flow | -$70.9M | -$128.7M+19.2% | -$159.4M-35.9% | -$117.3M-21.7% | -$96.4M-24.5% | -$77.4M-99.5% | -$38.8M-944.8% | -$3.7M |
| Investing Cash Flow | $41.1M | $134.3M-4.3% | $140.3M+210.5% | -$127.0M+15.4% | -$150.2M-303.8% | $73.7M+135.0% | -$210.9M-1076.0% | -$17.9M |
| Financing Cash Flow | -$32.1M | -$31.7M-237.1% | $23.1M-91.6% | $274.4M+21.0% | $226.9M+8877.2% | $2.5M-98.8% | $213.2M+368.2% | $45.5M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
PLRX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | -11654.8% | -1313.4% | -1288.1% | -99.6%-97.4pp | -2.2% |
| Net Margin | N/A | N/A | 10208.9% | -1273.3% | -1284.5% | -99.3%-98.2pp | -1.1% |
| Return on Equity | 82.4%+13.2pp | 69.2%+35.1pp | 34.1%+73.4pp | -39.4%+9.5pp | -48.9%-34.2pp | -14.7% | N/A |
| Return on Assets | 66.3%+13.3pp | 53.0%+21.5pp | 31.5%+66.7pp | -35.2%+8.8pp | -44.0%-29.9pp | -14.1%-13.5pp | -0.5% |
| Current Ratio | 12.00+1.1x | 10.91-6.8x | 17.72+3.5x | 14.23+1.8x | 12.44-12.6x | 25.07+11.4x | 13.69 |
| Debt-to-Equity | 0.00-0.1x | 0.10+0.1x | 0.020.0x | 0.030.0x | 0.000.0x | 0.04 | N/A |
| FCF Margin | N/A | N/A | -7422.9% | -995.3% | -1022.1% | -92.8%-86.3pp | -6.5% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Pliant Therapeutics, Inc. Ranks
Frequently Asked Questions
What is Pliant Therapeutics, Inc.'s annual revenue?
Pliant Therapeutics, Inc. (PLRX) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Pliant Therapeutics, Inc. profitable?
Yes, Pliant Therapeutics, Inc. (PLRX) reported a net income of $149.3M in fiscal year 2025.
What is Pliant Therapeutics, Inc.'s EBITDA?
Pliant Therapeutics, Inc. (PLRX) had EBITDA of -$154.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Pliant Therapeutics, Inc. have?
As of fiscal year 2025, Pliant Therapeutics, Inc. (PLRX) had $45.4M in cash and equivalents against $0 in long-term debt.
What is Pliant Therapeutics, Inc.'s return on equity (ROE)?
Pliant Therapeutics, Inc. (PLRX) has a return on equity of 82.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Pliant Therapeutics, Inc.'s free cash flow?
Pliant Therapeutics, Inc. (PLRX) recorded an outflow of $128.7M in free cash flow during fiscal year 2025. This represents a 19.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Pliant Therapeutics, Inc.'s operating cash flow?
Pliant Therapeutics, Inc. (PLRX) recorded an outflow of $128.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Pliant Therapeutics, Inc.'s total assets?
Pliant Therapeutics, Inc. (PLRX) had $225.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Pliant Therapeutics, Inc.'s capital expenditures?
Pliant Therapeutics, Inc. (PLRX) invested $374K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Pliant Therapeutics, Inc. spend on research and development?
Pliant Therapeutics, Inc. (PLRX) invested $109.2M in research and development during fiscal year 2025.
What is Pliant Therapeutics, Inc.'s current ratio?
Pliant Therapeutics, Inc. (PLRX) had a current ratio of 12.00 as of fiscal year 2025, which is generally considered healthy.
What is Pliant Therapeutics, Inc.'s debt-to-equity ratio?
Pliant Therapeutics, Inc. (PLRX) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Pliant Therapeutics, Inc.'s return on assets (ROA)?
Pliant Therapeutics, Inc. (PLRX) had a return on assets of 66.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Pliant Therapeutics, Inc.'s Altman Z-Score?
Pliant Therapeutics, Inc. (PLRX) has an Altman Z-Score of -5.67, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Pliant Therapeutics, Inc.'s Piotroski F-Score?
Pliant Therapeutics, Inc. (PLRX) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Pliant Therapeutics, Inc.'s earnings high quality?
For every $1 of reported earnings, Pliant Therapeutics, Inc. (PLRX) used $0.86 of operating cash (-$128.3M OCF vs $149.3M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Pliant Therapeutics, Inc. cover its interest payments?
Pliant Therapeutics, Inc. (PLRX) reported an operating loss of $156.4M against $2.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.